From Self-sufficiency
Jump to: navigation, search
File:Panobinostat structure.svg
Systematic (IUPAC) name
CAS Number 404950-80-7
ATC code none
PubChem CID 6918837
Chemical data
Formula C21H23N3O2
Molar mass 349.42622 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Panobinostat (LBH-589) is an experimental drug developed by Novartis for the treatment of cancer. As of December 2008, it is being tested against cutaneous T cell lymphoma (CTCL), chronic myelogenous leukemia, myelodysplastic syndromes, breast cancer, prostate cancer and other types of malignant disease in a number of Phase II and III clinical trials,[1][2] for example a Phase III study for CTCL.[3]

Panobinostat has been found to synergistically act with sirolimus to kill pancreatic cancer cells in the laboratory in a Mayo Clinic study. In the study, investigators found that this combination destroyed up to 65 percent of cultured pancreatic tumor cells. The finding is significant because the three cell lines studies were all resistant to the effects of chemotherapy – as are many pancreatic tumors.[4]

Mechanism of action

Panobinostat inhibits one or more of the histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple pathways.[5]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. LBH-589
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. NCT00425555 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
  4. Mayo Clinic Researchers Formulate Treatment Combination Lethal To Pancreatic Cancer Cells
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.